medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2009, Number 1

<< Back Next >>

Neumol Cir Torax 2009; 68 (1)

Treatment outcome with a standardized regimen for Patients with multidrug-resistant tuberculosis (MDR-TB). National institute of Respiratory Diseases “Ismael Cosío Villegas”. México 2003-2005

Martínez MD, Torres CA, Villarreal VH, Báez SR, Salazar LMA

Language: Spanish
References: 45
Page: 7-16
PDF size: 72.44 Kb.


ABSTRACT

Objective: To evaluate the treatment outcome with standardized regimen for Patients with multidrug-resistant tuberculosis (MDR-TB) and to measure its efficacy and efficiency. Methods: Study retrospective with clinical charts of patients with TB-MDR from June 2003 to June 2005. Demographics, history of drugs and clinical regimen of retreatment and outcome where analyzed. Results. Among 55 patients initiated retreatment, the mean of drug resistance was 3.3, patient where treated with a median of 4 (4-6) drugs. There where monitoring adverse effects in 91.7% patients, of them, 93.2% had at least one. Probable cure 66.7%, failure 18.8%, default 6.3%, death 6.3% and it had to suspended retreatment on 2.1% cause severe adverse effects. The efficiency was 58.2% (32/55) and the efficacy was 80% (32/40). The antecedent of contact with a TB patient had greater favorable results that the ones that did not have it [OR: 3.6 (IC95% 0.95-15.19) p = 0.03]. The patients from Veracruz had more unfavorable results that the other ones [OR: 6.4 (IC95% 1.46-32.20) p = 0.004]. Conclusion: The results suggest that the retreatment standardized is efficient above those patients had treated only with first line drugs and it had efficacy mainly in those patients treated under DOTS/TAES strategy.


REFERENCES

  1. Abdel AM, Wright A, Laszlo A, De-Muynck A, Portaels F, Van DA, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154.

  2. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim S J, Tlali E, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5(10): 887-893.

  3. Nettleman MD. Multidrug-resistant tuberculosis news from the front. JAMA 2005; 293(22): 2788-2790.

  4. Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance, 1999-2002. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.343).

  5. Regional Plan for Tuberculosis control, 2006-2015. Pan American Health Organization Washington, D.C: PAHO, 2006.

  6. Dirección General de Epidemiología. Secretaría de Salud, México. Anuarios de Morbilidad 1984-2004 Versión 2.0 (Anuarios de Morbilidad 84-04/DGE/SSA).

  7. Global tuberculosis control: surveillance, planning, financing. WHO report 2003. Geneva, World Health Organization, 2003 (WHO/CDC/TB/2003.316).

  8. Global tuberculosis control: surveillance, planning, financing. WHO report 2004. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.331).

  9. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva, World Health Organization, 2005 (WHO/HTM/TB/2005.349).

  10. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.362).

  11. Granich RM, Balandrazo S, Santaella AJ, Binkin NJ, Castro KG, Márquez-Fiol A, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997. Arch Intern Med 2000; 160: 639-644.

  12. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006 Aug; 10(8): 829-37.

  13. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.

  14. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).

  15. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese inmigrants. Int J Tuberc Lung Dis 2005; 9(2): 164-169.

  16. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of Multidrug-Resistant Tuberculosis in San Francisco: An Outpatient-Based Approach. CID 2005; 40 (1 April).

  17. Ollé-Goig JE, Sandy R. Outcomes of individualized treatment for multidrug-resistant tuberculosis before DOTS-Plus. Int J Tuberc Lung Dis 2005; 9(7): 765-770.

  18. Escudero E, Peña JM, Álvarez-Sala R, Vázquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis 2006; 10(4): 409-414.

  19. Flement-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of Multi-drug-resistant Tuberculosis in France A Nationwide Case-Control Study. Am J Respir Crit Care Med 1999; 160: 587-593.

  20. Holtz TH, Sternberg M, Kammerer S, Laserson K F, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.

  21. Van DA, Hamid SM, Kumar DA, Bastian I, Portales F. Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8(5): 560-567.

  22. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8(3): 361-368.

  23. Guía para la atención de pacientes con tuberculosis multifarmacorresistente. México Secretaría de Salud, 2004 (ISBN: 970-721-175-X).

  24. Wai YW, Kuen CC, Hung CC, Ming TC, Chiu LC, Chuen WP, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. CHEST 2000; 117: 744-751.

  25. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9(5): 507-513.

  26. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993 prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.

  27. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.

  28. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.

  29. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at chest clinic. Int J Tuberc Lung Dis 2001; 5(12): 1129-1136.

  30. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.

  31. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.

  32. Park SK, Tim SD, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2(11): 877-884.

  33. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10(4): 402-409.

  34. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MN, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.

  35. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.

  36. Tahaolu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Özmen I, Kapakli N. The Treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.

  37. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug-resistant tuberculosis. WHO/TB96.210. Geneva, Switzerland: WHO, 1997.

  38. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9(6): 640-645.

  39. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vázquez R, López-Segundo E, Villarreal-Velarde H, Quiñones-Falconi F y cols. Resultados de tratamiento de tuberculosis resistente en 91 pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Rev Inst Nal Enf Resp Mex 2004; 17(1): 15-21.

  40. Kritski AL, Rodrigues LS, Andrade M K, Werneck-Barroso E, Monteiro MA, Haffner A, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111(5): 1162-1167.

  41. Espinal MA, Kim SJ, Suarez PG, Man KK, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283(19): 2537-2545.

  42. DeRiemer K, García-García L, Bobadilla-del-Valle M, Palacios-Martínez M, Martínez-Gamboa A, Small PM, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.

  43. Shin S, Furin J, Bayona J, Mate K, Yong KJ, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Social Science & Medicine 2004; 59: 1529-1539.

  44. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 10(11):1185-1187.

  45. The Global Task Force on XDR-TB (Update February 2007). Stop TB Department. Geneva, World Health Organization.




2020     |     www.medigraphic.com